CSIMarket
 
Morphosys Ag  (NASDAQ: MOR)
 

Morphosys Ag's Customers Performance

MOR



 
MOR's Source of Revenues During the corresponding time, Morphosys Ag saw a revenue deteriorated by -14.37 % year on year, While revenue at the Morphosys Ag's corporate clients

List of MOR Customers




for the same period Morphosys Ag revnue deteriorated by -14.37 % year on year,

List of MOR Customers

Morphosys Ag's Business Units






Morphosys Ag's Comment on Sales, Marketing and Customers



The company utilizes third parties, including research and medical institutions, clinical investigators, contract research organizations (CROs), service providers, and collaboration partners, to conduct development activities such as preclinical studies, quality testing, clinical trials, data collection, analysis, and reporting. These third parties are involved in both early and late phase product development. The company also relies on suppliers for drug substances and drug products, facing risks if suppliers prioritize other customers or if replacement suppliers require qualification and regulatory approval. Compliance with Good Practice (GxP) standards enforced by regulatory authorities, including the U.S. Food and Drug Administration (FDA) and authorities in the European Economic Area (EEA), is required.





Morphosys Ag’s Comment on Sales, Marketing and Customers


The company utilizes third parties, including research and medical institutions, clinical investigators, contract research organizations (CROs), service providers, and collaboration partners, to conduct development activities such as preclinical studies, quality testing, clinical trials, data collection, analysis, and reporting. These third parties are involved in both early and late phase product development. The company also relies on suppliers for drug substances and drug products, facing risks if suppliers prioritize other customers or if replacement suppliers require qualification and regulatory approval. Compliance with Good Practice (GxP) standards enforced by regulatory authorities, including the U.S. Food and Drug Administration (FDA) and authorities in the European Economic Area (EEA), is required.








MOR's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Morphosys Ag 650.57 266.87 -212.50 511
SUBTOTAL 0.00 0.00 0.00 -

Sources: Morphosys Ag’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Morphosys Ag’s corporate clients.
For your research, we’ve provided 9 tables on Morphosys Ag corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.